Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Liz Kane
Impactful Strategy